Generic drug of the therapeutic class: Anesthesia, resuscitation, analgesics
active ingredients: Main compartment A: Calcium chloride, Magnesium chloride, Sodium chloride, Small compartment B: [Sodium bicarbonate (E550i), 651], Final solution after mixing: Calcium chloride, Magnesium chloride, Sodium chloride, [Sodium bicarbonate (E550i), 651]
Solution for hemofiltration, hemodialysis and hemodiafiltration
Box of 2 Pouches (CLEAR-FLEX) of 5000 ml
Accusol 35 is indicated for the treatment of acute and chronic renal failure, as a replacement for haemofiltration and haemodiafiltration and as a dialysis solution in hemodialysis and haemodiafiltration.
Accusol 35 is primarily intended for patients with hyperkalemia.
Dosage ACCUSOL 35 Solution for hemofiltration, hemodialysis and haemodiafiltration Box of 2 Pouches (CLEAR-FLEX) 5000 ml
For haemofiltration, hemodialysis and haemodiafiltration.
Accusol 35 as a substitute
The amount of substitution solution to be administered to an adult patient is determined by the prescribed ultrafiltration rate and is defined individually for each case to ensure adequate fluid and electrolyte balance.
· Chronic renal failure: 7 to 35 ml / kg / hour.
· Acute renal failure: 20 to 35 ml / kg / hour.
The elderly :
As for adults. Fluid volume recommendations may be adjusted by the attending physician based on the clinical condition of the patient.
Accusol 35 is administered into the extracorporeal bloodstream in pre- or post-dilution mode as prescribed by the physician.
Accusol 35 as a dialysis solution
The mode and frequency of treatment, the volume of the exchange, the stasis time and the length of the dialysis session should be determined by the attending physician according to the clinical condition of the patient.
Administration mode :
· Hemodialysis: via dialysis dialysis compartment.
· Hemofiltration: via extracorporeal arterial or venous circulation.
The ready-to-use solution Accusol 35 is obtained after mixing the solution of the large compartment A and the solution of the small compartment B, after having opened the intercomparable peel weld. For more information on the use of this medicine, see the section Instructions for use, handling and disposal .
Contraindications dependent on the solution:
· Hypokalemia, in the absence of simultaneous and adapted potassium supplementation;
· Metabolic alkalosis.
Contraindications related to the technique of haemofiltration / hemodialysis and haemodiafiltration:
· Renal failure with aggravated hypercatabolism in cases where uremic symptoms are no longer relieved by haemofiltration;
· Inadequate blood flow from vascular access;
· High risk of hemorrhage caused by systemic anticoagulation.
Adverse effects Accusol 35
The undesirable effects indicated are the adverse effects observed in clinical trials that have been evaluated by the investigator as related to Accusol (see 1 / Clinical Studies) and those observed in the literature (see 2 / Literature Review).
To date, no adverse effects are based on post-marketing experience.
The frequencies are defined as follows:
Very common (> 1/10), common (> 1/100, 1/1000, 1/10 000, <1/1000) and very rare (<1/10 000).
1 / Clinical studies
Linked to the procedure
Linked to the solution
Metabolism and nutrition disorders
2 / Review of the literature
The undesirable effects listed below can be observed with haemofiltration and hemodialysis solutions:
· Those related to the procedure may include: nausea, vomiting, muscle cramps, hypotension, bleeding, coagulation, infection and air embolism.
· Those related to the solution may include: metabolic alkalosis, electrolyte and / or fluid imbalances, hypophosphatemia, hypoglycemia, hypo- and hypervolemia, hypo- and hypertension.